


Charity registration number 1143743

Company registration number 07767248 (England and Wales)

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2023



THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Mr Percy Beckley Mr Jonathan S M Craft Mr Maurice H Craft Mrs Rachel L Craft Mrs Michaela M Rees Jones Mr Laurence J F Tarlo
Ambassadors	Ms Tiffany Chawner Ms Nicola Floyd Mr Julian O'Dell Mrs Cheryl Whitehead
Patrons	Lord Alliance CBE Harry & Carolyn Black Barry Boas Roger Cadbury Family Harold & Daphne Cooper Charitable Trust Peter & Marilyn Cooper John Emery Alessandro Dusi Isabel Ettedgui The Fallon Family Charles & Diane Herlinger Michael & Lottie Hunter Bevs Malim Martin O'Connor Sir Paul & Lady Ruddock Chris Sharp Michaela M Rees Jones
Secretary	Mrs Joyce Fletcher (JP)
Charity number	1143743
Company number	07767248
Principal address	2 Regency Chambers Jubilee Way Bury Lancashire BL9 0JW
Registered office	2 Regency Chambers Jubilee Way Bury Lancashire BL9 0JW

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
LEGAL AND ADMINISTRATIVE INFORMATION

Accountants

JS. Accountants & Business Advisors Limited
James House
Stonecross Business Park
Yew Tree Way
Warrington
Cheshire
WA3 3JD

Bankers

Virgin Money
17-21 Oxford Street
Bolton
Lancashire
BL1 1RD

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED

ACTION AGAINST CANCER

CONTENTS

	Page
Chairman's statement	1
Trustees' report	2 - 7
Independent examiner's report	8
Statement of financial activities	9 - 10
Balance sheet	11
Statement of cash flows	12
Notes to the financial statements	13 - 19

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
CHAIRMAN'S STATEMENT

FOR THE YEAR ENDED 30 SEPTEMBER 2023

The Trustees are very pleased that the charity continues to make a positive contribution in the field of research improving cancer diagnostics and treatments.

As in previous years, Action Against Cancer funded groundbreaking research at Imperial College, London and at two laboratories at the University of Sussex. In addition, this year we part funded the establishment of a new research facility at Anglia Ruskin University, Cambridge ('ARU'). Excellent progress has been made at this new laboratory, with the recruitment of two Postdoctoral Research Fellows who have begun promising projects. There are more details in this report.

During this year a number of significant papers were published with results from research funded by Action Against Cancer. As stated in the acknowledgments of one of these papers by the scientist leading the work, the team *"thank the late Hilary Craft OBE, the visionary founder of Action Against Cancer, whose unwavering support made this research possible."*

Fundraising has not as yet recovered since the Covid pandemic. However, committed supporters of Action Against Cancer made generous donations and organised wonderful events. I would like to personally thank them and all of the Patrons, Ambassadors, individuals, companies, charitable trusts and foundations who continue to support Action Against Cancer. Working together we can make a tangible difference for cancer patients.



Mr Maurice H Craft
Chairman

Date: 28 June 2024

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED

ACTION AGAINST CANCER

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 30 SEPTEMBER 2023

The Trustees present their report and financial statements for the year ended 30 September 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

The objectives of the charity have remained unchanged. These are to promote and protect the health of the public, in particular by research into the prevention, treatment and cure for all forms of cancer. This includes research into practical applications for the prevention, treatment and cure of cancer and to disseminate the useful results of such research to the public. The Charity Commission's general guidance on public benefit has been referred to when reviewing our aims and objectives and in planning our future activities.

Scientific Advisory Board

Action Against Cancer is privileged that the following scientists and clinicians have agreed to serve on our Scientific Advisory Board:

Professor Heinz-Josef Lenz - Deputy Director for Research Program and Head of the Gastrointestinal Cancer Program, USC Norris Comprehensive Cancer Centre

Dr Abby Siegel - Assistant Professor, Department of Medicine, Columbia University Medical Centre, New York

Dr Siddhartha Mukherjee - Associate Professor of Medicine, Columbia University Medical Centre, New York

Professor Pramod K. Srivastava - Director, Carole and Ray Neag Comprehensive Cancer Centre, Connecticut

Research Themes

All work funded by Action Against Cancer falls under the following research themes:

Cancer Stem Cells
Genetic Switches
Developing a drug for a totally new approach to therapy (LMTK3)
Understanding the Cancer Brain
Metastasis

Cancer Stem Cells

Cancer Stem Cells (CSCs) only constitute up to 5% of a cancerous tumour, but they generate the fast multiplying cells that make up the majority of the rest. CSCs are also linked to some of the most malignant features of cancer, including treatment resistance and the ability to spread to other parts of the body.

It can be many months or even years after successful treatment of a primary tumour, before secondary cancer spreads. This has been described as if the dandelion has been removed from the lawn, but the CSC root is left below the surface to regrow at a later date.

Action Against Cancer is funding a number of projects examining CSCs, to enable the development of treatments that specifically target them - to more fully cut cancers out by the roots. The scientists are working to gain a thorough understanding of how CSCs operate and to answer vital questions such as:

- Why do certain patients not respond to treatments?
- What conditions allow some tumours to spread around the body?
- How could future treatments specifically target the most malignant cells?

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

EXAMPLE OF PROGRESS: Genetic diversity of cancer cells research

A research team funded by Action Against Cancer at Imperial College, London has further developed a powerful genetic system they designed allowing them to manipulate genes in cancer cells. The next stage in the research has also now been achieved, with the development and integration of specialist procedures and equipment.

Using a time-lapse microscopy technique, detailed 3D images of cancer cell cultures were captured at regular intervals over a specific time period. This allowed for detailed segmentation and classification of cancer gene nuclei. In combination with other advanced analysis techniques developed by the team led by Dr Nina Moderau, they have gained a deeper understanding of the genetic diversity and cell competition observed in certain cancers. The aim is for this knowledge to inform the development of more effective therapies and improve the ability to predict and manage cancer treatment outcomes.

Genetic Switches

Since the mapping of DNA with the Human Genome Project, there is greater understanding within the scientific community of some aspects of cancer. In the past, the vast majority of DNA was believed to be 'junk' as it does not code for protein. It was thought only a small amount of DNA was significant, that which turns into single stranded RNA, and then into proteins responsible for the structures and functions we are familiar with (brown hair, blue eyes etc).

However, it is now known that much of DNA is in fact transcribed into non-coding RNAs, some of which play important roles in normal biological function, gene regulation and cancer development. Action Against Cancer is funding a range of projects related to identifying non-coding RNAs that are operating as genetic switches causing cancer to grow or shrink.

EXAMPLE OF PROGRESS: Pregnancy and breast cancer discovery

A groundbreaking study funded by Action Against Cancer examined how having children affects a woman's risk of breast cancer, and the findings were published in a paper in the prestigious journal Nature.

In research led by Dr Biancastella Cereser's team at Imperial College, London, the team discovered that pregnancy can actually change the genetic makeup of breast tissue. Just like wrinkles appear on the skin with age, changes can also happen in the DNA of breast cells over time. The study showed that pregnancy adds an extra twist to these changes. In older women who become mothers for the first time, the number of these changed cells gets bigger compared to younger mothers or older women without children. This might mean that older first-time mothers could have a higher chance of having harmful changes in their breast cells compared to other women.

This new knowledge can empower women to make informed choices about their reproductive health and to take steps to prevent and detect breast cancer early.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

Developing a drug for a totally new approach to therapy (LMTK3)

The identification of a new cancer causing gene in 2011 by Professor Georgios Giamas was the earliest significant breakthrough supported by Action Against Cancer. This gene called LMTK3 is new to humans, and is expressed more in cancer cells than in normal cells. Those cancers that have high levels of LMTK3 are also much more aggressive.

Since 2011 we have funded Professor Giamas' research aiming to develop an anti-LMTK3 drug. This would be to overcome the resistance to treatments that often develops within patients' bodies.

Many patients respond well to initial treatment but then develop resistance to it – this is when, with currently available treatments, their cancer becomes much more difficult to treat. A potential anti-LMTK3 drug will be specifically designed to work in conjunction with a patient's existing treatment, and in a way that overcomes chemotherapy or hormonal therapy resistance, allowing these treatments to start working again. This would be a momentous step in the history of cancer treatment.

EXAMPLE OF PROGRESS: Drug discovery developments

The team working on this pioneering project have used structural biology experiments to generate new findings that demonstrate the binding efficiency of certain drug compounds to LMTK3. This is an important step as it means the compounds can now be chemically altered in order to make them bind more effectively to LMTK3.

The contribution of LMTK3 in the behaviour of immune cells in certain cancer types is also being investigated. The researchers have explored the mechanism implicated in this process by performing a variety of different experiments to determine what changes occur inside the immune cells, when LMTK3 is overexpressed, that makes them less able to attack the cancer cells.

Understanding the Cancer Brain

It is thought that cancer cells have a 'brain', which is responsible for turning the cells 'on' or 'off'. We are funding research to gain a comprehensive understanding of this cancer brain, by learning exactly what takes place during the onset and growth of cancer – one protein at a time.

Proteins are present in all of the cells in our body, including in cancer cells. The types of proteins, their quantity, and the level of their activity can differ between normal cells and cancer cells. Proteins enable cancer cells to grow very fast or they can cause them not to respond to a given drug. One of the main approaches in studying cancer cells and identifying new treatment targets is to analyse their protein content in great detail.

Action Against Cancer supports research to understand cancer cells, to pave the way for the design of drugs targeting those proteins that are found to play the most important role in the progression of cancer.

EXAMPLE OF PROGRESS: Brain cancer discovery

A team at the University of Sussex made a discovery that could help to increase life expectancy and improve treatment for an aggressive brain cancer, which impacts thousands of people every year in the UK, and hundreds of thousands worldwide.

In the Action Against Cancer funded study, the researchers demonstrated that an understudied protein called PANK4, is able to block cancer cells from responding to chemotherapeutic treatment for the highly intrusive brain cancer, glioblastoma.

The team further showed that if the protein is removed, cancer cells respond to the main chemotherapy drug used globally for the treatment of glioblastoma. They now hope to develop a drug to reverse chemo-resistance and improve outlook for patients.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

Metastasis

When cancer is said to have spread this means it has metastasised. This is when cancer cells break away from where they first formed and travel through the blood or lymphatic systems to form new tumours in other parts of the body. This development of secondary cancer is called metastasis. A metastatic tumour is the same type of cancer as the primary tumour.

Action Against Cancer funds a number of projects that are linked to understanding the causes of metastasis, in order to:

- more effectively predict the likelihood of cancerous cells metastasising (spreading) in each patient.
- tailor the testing for patients with a high likelihood of their cancer metastasising so as to improve the likelihood of early diagnosis.
- improve the treatment strategies for these patients once a propensity for metastasis of their cancer has been identified, thus greatly increasing their chances of survival.

EXAMPLE OF PROGRESS: Breast cancer cell communication

Breast Cancer is the most common form of cancer worldwide, responsible for 25% of cancers in women. Whilst treatment is effective and curative in early breast cancer, metastatic disease is incurable. The tumour microenvironment of breast cancer plays an important role in whether the disease will grow and spread to other parts of the body, and how it will respond to treatment.

A project at the new research facility at Anglia Ruskin University, Cambridge, part funded by Action Against Cancer, is delving into the intricate dynamics of breast cancer. The team is exploring the relationship between tumour cells and the surrounding tissue, with a particular focus on the role of fatty tissue. By studying how fatty tissue cells and tumour cells collaborate in guiding communication pathways, the research aims to bridge gaps in understanding their molecular interactions. If the research identifies new fatty and/or cancer molecules that play a crucial role in these processes, improved diagnostics and treatments can be developed.

Achievements and performance

Income continues to remain at a much lower level than during pre-Covid pandemic times. A small number of fundraising events took place during the year, including notably Catfest and A Movable Feast, which combined raised more than £100,000.

Everyone involved with Action Against Cancer is enormously grateful to the individuals, companies and trusts and foundations that have donated towards our work.

We are incredibly proud of the groundbreaking work the scientists in the laboratories at Imperial College, London, the University of Sussex and Anglia Ruskin University, Cambridge have achieved during the year.

Below is a sample of published papers describing work wholly or partly funded by Action Against Cancer:

1. The mutational landscape of the adult healthy parous and nulliparous human breast
2. The role of non-coding RNAs in extracellular vesicles in breast cancer and their diagnostic implications
3. Comparison of phenomics and cfDNA in a large breast screening population: the Breast Screening and Monitoring Study (BSMS)
4. The inhibitory properties of a novel selective LMTK3 kinase inhibitor

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

Financial review

During the year the charity's income from all sources amounted to £325,365 (2022: £508,226). In the same period, expenditure on charitable activities totalled £389,577 (2022: £477,732), and the cost of raising funds totalled £72,566 (2022: £71,907).

Accumulated funds as at 30 September 2023 totalled £2,046,815 (2022: £2,183,593). The Trustees consider that the financial position as at 30 September 2023 is satisfactory. Approximately two-thirds of these funds (including those in unrestricted funds) have been awarded to approved projects (see Note 13).

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six months expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Plans for the future

The charity will continue to fund all of the projects already approved, and to fundraise to support other research aiming to further understand cancer and how to better diagnose and treat it. The charity will continue to disseminate results of research in published scientific papers, on the organisation's website and in regular e-newsletters.

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 8 September 2011 and registered with the Charity Commission on 9 September 2011. The charity carries out its activities using the working name Action Against Cancer.

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Mr Percy Beckley
Mr Jonathan S M Craft
Mr Maurice H Craft
Mrs Rachel L Craft
Mrs Michaela M Rees Jones
Mr Laurence J F Tarlo

The Board of Trustees is authorised to appoint new Trustees to fill vacancies arising through the resignation or death of an existing trustee.

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

The charity benefits from the provision of accommodation and administrative support from QF Holdings NW Limited, a company that is controlled by certain of the Trustees of the charity. No monetary value can be attributed to this support, and therefore it is not included in the financial statements.

There are no other transactions with related parties. The Trustees maintain a register of interests, which is updated at every meeting.

The Trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects.

Procedures are in place to ensure compliance with health and safety of staff, volunteers, clients and visitors.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

On behalf of the board of trustees



Mr Maurice H Craft

Trustee

Dated: 28 June 2024

**THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
INDEPENDENT EXAMINER'S REPORT**

TO THE TRUSTEES OF THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED

I report to the Trustees on my examination of the financial statements of The Hilary Craft Charitable Foundation Limited (the charity) for the year ended 30 September 2023.

Responsibilities and basis of report

As the Trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

E. P. Atkinson

JS. Accountants & Business Advisors Limited

Peter Atkinson F.C.A

James House
Stonecross Business Park
Yew Tree Way
Warrington
Cheshire
WA3 3JD

Dated: 28 June 2024

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 30 SEPTEMBER 2023

Current financial year

		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Total 2022 £
	Notes				
<u>Income from:</u>					
Voluntary income	2	182,550	100,197	282,747	501,221
Investments	3	42,618	-	42,618	7,005
Total income		<u>225,168</u>	<u>100,197</u>	<u>325,365</u>	<u>508,226</u>
<u>Expenditure on:</u>					
Raising funds	4	72,566	-	72,566	71,907
Charitable activities	5	377,059	12,518	389,577	477,732
Total		<u>449,625</u>	<u>12,518</u>	<u>462,143</u>	<u>549,639</u>
Net (expenditure)/income for the year/ Net movement in funds		(224,457)	87,679	(136,778)	(41,413)
Fund balances at 1 October 2022		<u>2,171,316</u>	<u>12,277</u>	<u>2,183,593</u>	<u>2,225,006</u>
Fund balances at 30 September 2023		<u><u>1,946,859</u></u>	<u><u>99,956</u></u>	<u><u>2,046,815</u></u>	<u><u>2,183,593</u></u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED)
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 30 SEPTEMBER 2023

Prior financial year

		Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
	Notes			
<u>Income from:</u>				
Voluntary income	2	464,027	37,194	501,221
Investments	3	7,005	-	7,005
Total income		471,032	37,194	508,226
<u>Expenditure on:</u>				
Raising funds	4	71,907	-	71,907
Charitable activities	5	339,665	138,067	477,732
Total		411,572	138,067	549,639
Net (expenditure)/income for the year/ Net movement in funds		59,460	(100,873)	(41,413)
Fund balances at 1 October 2021		2,111,856	113,150	2,225,006
Fund balances at 30 September 2022		2,171,316	12,277	2,183,593

The statement of financial activities includes all gains and losses recognised in the year.

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
BALANCE SHEET

AS AT 30 SEPTEMBER 2023

	Notes	2023 £	£	2022 £	£
Current assets					
Debtors	10	436		391	
Cash at bank and in hand		2,100,020		2,239,418	
		<u>2,100,456</u>		<u>2,239,809</u>	
Creditors: amounts falling due within one year	11	(53,641)		(56,216)	
Net current assets		<u>2,046,815</u>		<u>2,183,593</u>	
Funds of the charity					
Restricted funds	12	99,956		12,277	
Unrestricted funds:					
General unrestricted funds		705,222		658,197	
Designated funds	13	1,241,637		1,513,119	
		<u>2,046,815</u>		<u>2,183,593</u>	

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 30 September 2023.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 28 June 2024



Mr Maurice H Craft
Trustee

Company Registration No. 07767248

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 SEPTEMBER 2023

	Notes	2023 £	£	2022 £	£
Cash flows from operating activities					
Cash absorbed by operations	16		(182,016)		(70,578)
Investing activities					
Investment income received		42,618		7,005	
Net cash generated from investing activities			42,618		7,005
Net cash used in financing activities			-		-
Net decrease in cash and cash equivalents			(139,398)		(63,573)
Cash and cash equivalents at beginning of year			2,239,418		2,302,991
Cash and cash equivalents at end of year			<u>2,100,020</u>		<u>2,239,418</u>

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

Charity information

The Hilary Craft Charitable Foundation Limited is a private company limited by guarantee incorporated in England and Wales and a registered charity in England and Wales. The registered office is 2 Regency Chambers, Jubilee Way, Bury, Lancashire, BL9 0JW.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Donated services are recognised as income when the charity has control over the item, any conditions associated with the item have been met, the receipt of the economic benefit from the use by the charity of the item is probable and the economic benefit can be measured reliably.

On receipt, donated services are recognised on the basis of the value of the gift to the charity which is the amount the charity would be willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised on the accruals basis.

Fundraising costs are those incurred in generating funds and do not include the costs of disseminating information in support of the charitable activities.

Support costs are those cost incurred directly in support of expenditure of the objects of the charity.

Overhead costs are allocated on the basis of the actual spend by activity.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the charity transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

(Continued)

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Income from donations and legacies

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Donations and gifts	158,251	100,197	258,448	464,027	12,194	476,221
Fundraising events	24,299	-	24,299	-	25,000	25,000
	<u>182,550</u>	<u>100,197</u>	<u>282,747</u>	<u>464,027</u>	<u>37,194</u>	<u>501,221</u>

3 Income from investments

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Interest receivable	<u>42,618</u>	<u>7,005</u>

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

4 Raising funds

	Unrestricted funds	Unrestricted funds
	2023	2022
	£	£
Costs of generating voluntary income		
Travelling and subsistence	112	112
Printing, stationery and postage	2,006	1,091
Fundraising expenses	300	463
Other expenses	711	298
Advertising	-	475
Other fundraising costs	-	615
Staff costs	68,503	67,958
Insurance	934	895
	<u>72,566</u>	<u>71,907</u>
Costs of generating voluntary income	72,566	71,907

5 Charitable activities

	Unrestricted	Restricted	Total Unrestricted	Restricted	Total
	2023	2023	2023	2022	2022
	£	£	£	£	£
LMTK3 drug development	143,242	-	143,242	91,781	91,781
Cancer stem cells research	-	8,288	8,288	-	100,873
PhD and other student bursaries	-	-	-	64,622	64,622
Ovarian cancer research	-	-	-	12,627	12,627
Pancreatic cancer research	2,817	-	2,817	25,238	25,238
Genetic switches	51,178	-	51,178	66,530	66,530
Breast cancer research	176,321	4,230	180,551	73,850	37,194
Other research project	194	-	194	-	-
	<u>373,752</u>	<u>12,518</u>	<u>386,270</u>	<u>334,648</u>	<u>138,067</u>
	373,752	12,518	386,270	334,648	138,067
Share of governance costs (see note 6)	3,307	-	3,307	5,017	-
	<u>377,059</u>	<u>12,518</u>	<u>389,577</u>	<u>339,665</u>	<u>138,067</u>
	377,059	12,518	389,577	339,665	138,067
Analysis by fund					
Unrestricted funds	377,059	-	377,059	339,665	-
Restricted funds	-	12,518	12,518	-	138,067
	<u>377,059</u>	<u>12,518</u>	<u>389,577</u>	<u>339,665</u>	<u>138,067</u>
	377,059	12,518	389,577	339,665	138,067

The other research project is mainly in relation to a project on tumour micromanagement.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

6 Support costs

	Support costs £	Governance costs £	2023 £	2022 £
Audit fees	-	-	-	4,050
Independent examination fees	-	2,000	2,000	-
Bank charges	-	560	560	643
Professional fees	-	747	747	324
	<u>-</u>	<u>3,307</u>	<u>3,307</u>	<u>5,017</u>
Analysed between Charitable activities	<u>-</u>	<u>3,307</u>	<u>3,307</u>	<u>5,017</u>

Governance costs include £2,000 (2022: £4,050) in relation to accountancy fees payable to the independent examiner (2022: auditor). These services were donated by the independent examiner and hence are included within voluntary income.

7 Trustees

None of the Trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year. A close family member of a trustee was remunerated for administrative services provided in the year totalling £15,000 (2022: £15,000).

8 Employees

The average monthly number employees during the year was:

	2023 Number	2022 Number
Management	<u>2</u>	<u>2</u>
Employment costs	2023 £	2022 £
Wages and salaries	65,524	64,250
Social security costs	1,690	2,425
Other pension costs	1,289	1,283
	<u>68,503</u>	<u>67,958</u>

No employees had annual remuneration of £60,000 or more.

Many of the research projects involve the use of PhD students. Action Against Cancer is currently funding a number of PhD studentships and fellowships at Imperial College, London and ARU, Cambridge to support the research work.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

9 Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

10 Debtors

	2023	2022
	£	£
Amounts falling due within one year:		
Prepayments and accrued income	436	391

11 Creditors: amounts falling due within one year

	2023	2022
	£	£
Trade creditors	51,728	54,422
Other creditors	1,913	1,794
	<u>53,641</u>	<u>56,216</u>

12 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	Movement in funds			Movement in funds			
	Balance at 1 October 2021	Income	Expenditure	Balance at 1 October 2022	Income	Expenditure	Balance at 30 September 2023
	£	£	£	£	£	£	£
ARU Laboratory	-	-	-	-	95,967	-	95,967
Cancer stem cells research	113,150	-	(100,873)	12,277	-	(8,288)	3,989
Breast cancer research	-	37,194	(37,194)	-	4,230	(4,230)	-
	<u>113,150</u>	<u>37,194</u>	<u>(138,067)</u>	<u>12,277</u>	<u>100,197</u>	<u>(12,518)</u>	<u>99,956</u>

The research work being undertaken is described in detail in the Trustees' Report under Research Themes.

THE HILARY CRAFT CHARITABLE FOUNDATION LIMITED
ACTION AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2023

13 Designated funds

Out of the total funds of £2,046,815 available, including unrestricted income, funds have been awarded to approved projects where planned future expenditure over the next two years is calculated to be £1,341,593. Of this, £99,956 are restricted funds and £1,241,637 are unrestricted funds.

Designated funds were awarded to projects within the research themes shown in the table below.

Programme area	Funds designated	Restricted	Unrestricted	%
Genetic Switches	£203,434	£0	£203,434	15.2
LMTK3	£856,004	£0	£856,004	63.8
CSC's	£80,034	£3,989	£76,045	6.0
UCB	£14,618	£0	£14,618	1.1
Metastasis	£388	£0	£388	0.0
ARU Laboratory	£187,115	£95,967	£95,968	13.9
Total	£1,341,593	£99,956	£1,241,637	100.00

14 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 30 September 2023 are represented by:						
Current assets/(liabilities)	1,946,859	99,956	2,046,815	2,171,316	12,277	2,183,593
	<u>1,946,859</u>	<u>99,956</u>	<u>2,046,815</u>	<u>2,171,316</u>	<u>12,277</u>	<u>2,183,593</u>

15 Related party transactions

Other than as disclosed in note 7, there were no disclosable related party transactions during the year (2022 - none).

16 Cash generated from operations

	2023 £	2022 £
Deficit for the year	(136,778)	(41,413)
Adjustments for:		
Investment income recognised in statement of financial activities	(42,618)	(7,005)
Movements in working capital:		
(Increase) in debtors	(45)	(10)
(Decrease) in creditors	(2,575)	(22,150)
Cash absorbed by operations	<u>(182,016)</u>	<u>(70,578)</u>

17 Analysis of changes in net funds

The charity had no material debt during the year.